Supplemental Citicoline Administration to Reduce Lung Injury Efficacy Trial (SCARLET)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 6, 2023

Primary Completion Date

March 17, 2025

Study Completion Date

April 1, 2026

Conditions
COVID-19
Interventions
DRUG

Citicoline

i.v. bolus administration every 12 hours for 5 days.

DRUG

Saline/Placebo

i.v. administered every 12 hours as a 10 ml bolus for 5 days.

Trial Locations (1)

43210

The Ohio State Wexner Medical Center, Columbus

All Listed Sponsors
lead

Ohio State University

OTHER